Hong Kong Stock Movers | COFOE MEDICAL (01187) Climbs Over 3% in Late Trading; Core Product Categories Ramp Up in First Three Quarters, Driving Rapid Revenue Growth

Stock News11-12

According to an industry news report, shares of COFOE MEDICAL (01187) rose more than 3% in late trading. As of press time, the stock was up 3.05% at HK$27.72, with a turnover of HK$4.0741 million.

On the news front, COFOE MEDICAL recently released its earnings results, reporting revenue of RMB 3.191 billion for the first three quarters, a year-on-year increase of 33.08%, and net profit attributable to shareholders of RMB 305 million, up 17.30% year-on-year.

Analysts noted that the ramp-up of core product categories drove rapid revenue growth in the first three quarters. They are bullish on the continued volume growth of self-developed ventilators, which, combined with incremental contributions from CGM products and Philips collaboration products, is expected to sustain rapid earnings growth.

Public information shows that this year the company launched the AI-powered ventilator C11 and partnered with Rongxin to introduce the Dabai X3PRO pulmonary disease ventilator, continuously improving its product lineup. Rongxin's home ventilators have obtained U.S. FDA 510(k) clearance, and future shipments are expected to be supplemented by recurring mask consumable purchases, driving the business from equipment sales toward a "device + consumables + services" extension.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment